Rojas-Castro, MadelynVerdasca, NunoMonge, SusanaDe Mot, LauraneTrobajo-Sanmartín, CaminoDuffy, RóisínTúri, GergőKuliese, MonikaDuerrwald, RalfBorg, Maria-LouisePopovici, OdetteGomez, VerónicaMakarić, Zvjezdana LovrićLaunay, OdileMarques, Diogo F.P.Pozo, FranciscoWitdouck, ArneMartínez-Baz, IvánFitzgerald, MargaretOroszi, BeatrixJančorienė, LigitaBuda, SilkeDziugyte, AusraLazăr, MihaelaMachado, AusendaTabain, IrenaNguyen, Liem Binh LuongWagner, Eva RivasDufrasne, FrançoisCastilla, JesúsDomegan, LisaVelkey, ViktóriaMajauskaite, FaustaHackmann, CarolinNicolay, NathalieBacci, SabrinaRose, Angela M.C.European Hospital Vaccine Effectiveness Group2026-01-132026-01-132025-11-25Influenza Other Respir Viruses. 2025 Nov;19(11):e70191. doi: 10.1111/irv.701911750-2640http://hdl.handle.net/10400.18/10684We estimated COVID-19 vaccine effectiveness (VE) against PCR-confirmed SARS-CoV-2 hospitalization in patients ≥ 60 years with severe acute respiratory infection, using a multicenter, test-negative, case-control study across seven sites in six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9980 controls (5024 vaccinated; 50%). VE was 42% (95% CI: 15; 61) 14-59 days post-vaccination, 32% (95% CI: -1; 54) at 60-119 days, and 36% (95% CI: 2; 60) at 120-179 days, and no effect thereafter. Among adults aged 60-79 and ≥ 80 years, we observed moderate VE against COVID-19 hospitalization for up to 2 and 4 months, respectively.engCase–Control StudyElderlySevere Acute Respiratory Infection (SARI)Test‐Negative DesignVaccine EffectivenessVEBISCOVID-19Infecções RespiratóriasEstados de Saúde e da DoençaCuidados de Saúdejournal article10.1111/irv.701911750-265941290396